Dexmedetomidine is not a controlled substance. It carries no DEA schedule designation in the United States, and its FDA-approved labeling explicitly states this. Both the intravenous formulation (Precedex) and the newer sublingual film (Igalmi) are unscheduled. That said, it is a prescription medication, meaning you can’t obtain it without a healthcare provider’s order.
Why It’s Not Scheduled
The DEA assigns controlled substance schedules (I through V) based on a drug’s potential for abuse and physical dependence. Dexmedetomidine works differently from the sedatives that typically land on those schedules. It’s a selective alpha-2 adrenergic agonist, meaning it activates receptors in the brain that naturally dial down the “fight or flight” response. This produces sedation and mild pain relief, but through a mechanism distinct from opioids, benzodiazepines, or barbiturates. It doesn’t produce the euphoria or reward-seeking behavior that drives most drug abuse.
In Canada, dexmedetomidine is similarly classified as a prescription-only drug without controlled substance restrictions.
What Dexmedetomidine Is Used For
Dexmedetomidine has two primary FDA-approved uses. The first is sedation for adults who are intubated and on a ventilator in an intensive care unit, where infusions are limited to 24 hours. The second is sedation before or during surgical and other procedures in patients who are not intubated. In 2022, the FDA also approved a sublingual film version (Igalmi) for managing acute agitation in adults.
One reason clinicians favor dexmedetomidine in the ICU is that it provides sedation without significantly suppressing breathing. Patients sedated with it can often be roused and can cooperate with commands, which is useful during procedures like fiberoptic intubation where the patient needs to remain awake. Dose reductions are recommended for adults over 65 and for people with liver impairment.
Withdrawal Can Still Happen
Despite not being a controlled substance, dexmedetomidine can cause physical dependence when used continuously in the ICU. In one study of 98 ICU patients, 46% experienced withdrawal symptoms after their infusion was stopped. Withdrawal looks like a rebound of the body’s stress response: agitation, confusion, rapid heart rate, high blood pressure, nausea, sweating, and tremors.
The risk goes up with longer infusion times and in patients who were already taking opioids before their ICU stay. Pre-existing atrial fibrillation was the strongest independent risk factor, increasing the odds of withdrawal sixfold. To ease the transition off dexmedetomidine, clinicians sometimes switch patients to clonidine, a related drug that works on the same receptors but lasts longer and can be taken by mouth.
This withdrawal profile is worth understanding because “not a controlled substance” doesn’t mean “no risk of dependence.” It means the federal government hasn’t identified a pattern of recreational abuse significant enough to warrant scheduling.
Common Side Effects
The most notable side effects involve the heart and blood pressure. Dexmedetomidine slows the heart rate and lowers blood pressure, which is a direct extension of how it works. In standard clinical use, bradycardia (abnormally slow heart rate) has been reported in up to about 14% of patients. However, in specific high-risk settings like targeted temperature management at 33°C, that rate climbed to 66% in one study, reflecting how cooling the body compounds the drug’s heart-slowing effect.
Low blood pressure is also common and can require intervention, particularly during the initial loading dose. These cardiovascular effects are the main reason dexmedetomidine requires close monitoring, typically in an ICU or procedural setting with continuous heart rate and blood pressure tracking.
How It Compares to Controlled Sedatives
Most other sedatives used in similar clinical settings are controlled substances. Midazolam and lorazepam (benzodiazepines) are Schedule IV. Propofol is also Schedule IV. Fentanyl and morphine, often used alongside sedation in the ICU, are Schedule II. Dexmedetomidine stands out as an option that provides meaningful sedation without the regulatory restrictions, locked cabinets, and dispensing paperwork that come with scheduled drugs.
This doesn’t make it a casual medication. It’s still administered under close medical supervision, requires cardiac monitoring, and carries real risks. But from a legal and regulatory standpoint, it sits in the same category as an antibiotic or blood pressure medication: prescription required, no controlled substance designation.